Inhibitory Immune Checkpoint Molecules and Exhaustion of T cells in COVID-19

Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition

(2021) Aljosja Rogiers et al.   Journal for ImmunoTherapy of Cancer

Immune checkpoint inhibition in COVID-19: risks and benefits

(2021) Parmida Sadat Pezeshki et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

COVID-19 immune signatures reveal stable antiviral T cell function despite declining humoral responses

(2021) Agnes Bonifacius et al.   IMMUNITY

VISTA: A Target to Manage the Innate Cytokine Storm

(2021) Mohamed A. ElTanbouly et al.   Frontiers in Immunology

Reduced Expression of Autophagy Markers and Expansion of Myeloid-Derived Suppressor Cells Correlate With Poor T Cell Response in Severe COVID-19 Patients

(2021) Sergej Tomić et al.   Frontiers in Immunology

COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

(2021) Angelo Dipasquale et al.   Journal for ImmunoTherapy of Cancer

Immunotherapy may protect cancer patients from SARS-CoV-2 infection: a single-center retrospective analysis

(2021) Maria Antonietta Isgrò et al.   Journal of Translational Medicine

Pronounce expression of Tim-3 and CD39 but not PD1 defines CD8 T cells in critical Covid-19 patients

(2021) Mehdi Shahbazi et al.   MICROBIAL PATHOGENESIS

Risk of COVID ‐19 in Patients with Cancer Receiving Immune Checkpoint Inhibitors

(2021) Nikolai Klebanov et al.   ONCOLOGIST

Immune Profile in Patients With COVID-19: Lymphocytes Exhaustion Markers in Relationship to Clinical Outcome

(2021) Anna Bobcakova et al.   Frontiers in Cellular and Infection Microbiology

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

(2020) Nanshan Chen et al.   LANCET

Clinical Characteristics of Coronavirus Disease 2019 in China

(2020) Wei-jie Guan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan

(2020) Jasper Fuk-Woo Chan et al.   Emerging Microbes & Infections

COVID-19 in the heart and the lungs: could we “Notch” the inflammatory storm?

(2020) Paola Rizzo et al.   BASIC RESEARCH IN CARDIOLOGY

COVID-19 infection: the perspectives on immune responses

(2020) Yufang Shi et al.   CELL DEATH AND DIFFERENTIATION

Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure

(2020) Evangelos J. Giamarellos-Bourboulis et al.   Cell Host & Microbe

Functional exhaustion of antiviral lymphocytes in COVID-19 patients

(2020) Meijuan Zheng et al.   Cellular & Molecular Immunology

Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients

(2020) Hong-Yi Zheng et al.   Cellular & Molecular Immunology

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

(2020) Mingfeng Liao et al.   NATURE MEDICINE

Combinatorial Tim‐3 and PD‐1 activity sustains antigen‐specific Th1 cell numbers during blood‐stage malaria

(2020) Rebecca S. Dookie et al.   PARASITE IMMUNOLOGY

Impact of PD-1 blockade on severity of COVID-19 in patients with lung cancers

(2020) Jia Luo et al.   Cancer Discovery

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China

(2020) Chaomin Wu et al.   JAMA Internal Medicine

Demographic factors associated with toxicity in patients treated with anti-programmed cell death-1 therapy

(2020) Kaustav P Shah et al.   Cancer Immunology Research

The Role of PD-1 in Acute and Chronic Infection

(2020) Jil M. Jubel et al.   Frontiers in Immunology

Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19)

(2020) Bo Diao et al.   Frontiers in Immunology

COVID-19 and immune checkpoint inhibitors: initial considerations

(2020) Ryan J Sullivan et al.   Journal for ImmunoTherapy of Cancer

Identification of druggable inhibitory immune checkpoints on Natural Killer cells in COVID-19

(2020) Olivier Demaria et al.   Cellular & Molecular Immunology

Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019

(2020) Serena Di Cosimo et al.   EUROPEAN JOURNAL OF CANCER

Next-Generation Sequencing of T and B Cell Receptor Repertoires from COVID-19 Patients Showed Signatures Associated with Severity of Disease

(2020) Christoph Schultheiß et al.   IMMUNITY

Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression

(2020) Robin Jeannet et al.   INTENSIVE CARE MEDICINE

A Rapid Fatal Evolution of Coronavirus Disease-19 in a Patient With Advanced Lung Cancer With a Long-Time Response to Nivolumab

(2020) Lucia Bonomi et al.   Journal of Thoracic Oncology

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study

(2020) Marina Chiara Garassino et al.   LANCET ONCOLOGY

Checkpoint inhibitor pneumonitis mimicking COVID-19 infection during the COVID-19 pandemic

(2020) Hsu-Liang Chang et al.   LUNG CANCER

Determinants of COVID-19 disease severity in patients with cancer

(2020) Elizabeth V. Robilotti et al.   NATURE MEDICINE

Covid-19 Infection and the Host Genetic Predisposition: Does it Exist?

(2020) A VAŠKŮ   PHYSIOLOGICAL RESEARCH

COVID-19 and the Immune System

(2020) J PACES et al.   PHYSIOLOGICAL RESEARCH

Clinical characteristics of 82 cases of death from COVID-19

(2020) Bicheng Zhang et al.   PLoS One

Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis

(2020) Milos Jesenak et al.   Frontiers in Cellular and Infection Microbiology

On the use of immune checkpoint inhibitors in patients with viral infections including COVID-19

(2020) Thilo Gambichler et al.   Journal for ImmunoTherapy of Cancer

Unique immunological profile in patients with COVID-19

(2020) Stefania Varchetta et al.   Cellular & Molecular Immunology

T cell responses and therapies against SARS‐CoV‐2 infection

(2020) Salman M. Toor et al.   IMMUNOLOGY

COVID-19 and the newly rediscovered multidisciplinarity

(2020) Melissa Bersanelli   Immunotherapy

Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease

(2020) Marissa Herrmann et al.   Frontiers in Immunology

Elevated Exhaustion Levels of NK and CD8+ T Cells as Indicators for Progression and Prognosis of COVID-19 Disease

(2020) Mingyue Li et al.   Frontiers in Immunology

LAG-3: from molecular functions to clinical applications

(2020) Takumi Maruhashi et al.   Journal for ImmunoTherapy of Cancer

Immune-checkpoint inhibitors from cancer to COVID‑19: A promising avenue for the treatment of patients with COVID‑19 (Review)

(2020) Silvia Vivarelli et al.   INTERNATIONAL JOURNAL OF ONCOLOGY

Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset

(2020) Juan Francisco Gutiérrez-Bautista et al.   Frontiers in Immunology

Management of immune checkpoint therapy for patients with cancer in the face of COVID-19

(2020) Chen Shen et al.   Journal for ImmunoTherapy of Cancer

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry

(2020) Rose K.C. Moritz et al.   EUROPEAN JOURNAL OF CANCER

Enhanced expression of immune checkpoint receptors during SARS-CoV-2 viral infection

(2020) Narjes Saheb Sharif-Askari et al.   Molecular Therapy-Methods & Clinical Development

Immune Checkpoint Inhibition in Sepsis

(2019) Richard S. Hotchkiss et al.   CRITICAL CARE MEDICINE

CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer

(2019) Laura M. McLane et al.   Annual Review of Immunology

Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy

(2019) Irene Cortese et al.   NEW ENGLAND JOURNAL OF MEDICINE

HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules

(2019) Christin Ackermann et al.   Scientific Reports

Immune checkpoint inhibition in sepsis: a Phase 1b randomized study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of nivolumab

(2019) Richard S. Hotchkiss et al.   INTENSIVE CARE MEDICINE

TIGIT as an emerging immune checkpoint

(2019) H. Harjunpää et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

MERS-CoV and H5N1 influenza virus antagonize antigen presentation by altering the epigenetic landscape

(2018) Vineet D. Menachery et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Differential expression pattern of co-inhibitory molecules on CD4+ T cells in uncomplicated versus complicated malaria

(2018) Annemieke Abel et al.   Scientific Reports

INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study

(2018) Melissa Bersanelli et al.   Immunotherapy

The Emerging Role of CD244 Signaling in Immune Cells of the Tumor Microenvironment

(2018) Laura Agresta et al.   Frontiers in Immunology

Soluble immune checkpoints in cancer: production, function and biological significance

(2018) Daqian Gu et al.   Journal for ImmunoTherapy of Cancer

De-novo and acquired resistance to immune checkpoint targeting

(2017) Nicholas L Syn et al.   LANCET ONCOLOGY

Severe cytokine release syndrome in a patient receiving PD-1-directed therapy

(2017) Seth J. Rotz et al.   PEDIATRIC BLOOD & CANCER

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Overcoming T cell exhaustion in infection and cancer

(2015) Kristen E. Pauken et al.   TRENDS IN IMMUNOLOGY

VISTA Is an Immune Checkpoint Molecule for Human T Cells

(2014) J. L. Lines et al.   CANCER RESEARCH

The Transcription Factor FoxO1 Sustains Expression of the Inhibitory Receptor PD-1 and Survival of Antiviral CD8+ T Cells during Chronic Infection

(2014) Matthew M. Staron et al.   IMMUNITY

Inhibitory Receptor Expression Depends More Dominantly on Differentiation and Activation than “Exhaustion” of Human CD8 T Cells

(2013) Amandine Legat et al.   Frontiers in Immunology

In Vivo Blockade of the PD-1 Receptor Suppresses HIV-1 Viral Loads and Improves CD4+ T Cell Levels in Humanized Mice

(2012) B. E. Palmer et al.   JOURNAL OF IMMUNOLOGY

Indoleamine 2,3 dioxygenase and metabolic control of immune responses

(2012) David H. Munn et al.   TRENDS IN IMMUNOLOGY

The role of the PD-1 pathway in autoimmunity and peripheral tolerance

(2011) Brian T. Fife et al.   Annals of the New York Academy of Sciences

LAG-3, TGF- , and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L

(2011) C. L. Lucas et al.   BLOOD

Therapeutic blockade of PD-L1 and LAG-3 rapidly clears established blood-stage Plasmodium infection

(2011) Noah S Butler et al.   NATURE IMMUNOLOGY

Premature Terminal Exhaustion of Friend Virus-Specific Effector CD8+ T Cells by Rapid Induction of Multiple Inhibitory Receptors

(2010) S. Takamura et al.   JOURNAL OF IMMUNOLOGY

LAG-3 Regulates Plasmacytoid Dendritic Cell Homeostasis

(2009) C. J. Workman et al.   JOURNAL OF IMMUNOLOGY

Tim-3 expression defines a novel population of dysfunctional T cells with highly elevated frequencies in progressive HIV-1 infection

(2008) R. Brad Jones et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection

(2008) Shawn D Blackburn et al.   NATURE IMMUNOLOGY